Physician profile
Mohan Govindan
NPI 1437152246
$1,639.43
in general payments reported to CMS, 2019-2025
23 companies · $589 in 2025
The $589 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2023: $450 · 2024: $451 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $239.67 | 2024-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $215.05 | 2023-2024 | |
| Novo Nordisk INC | $207.07 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $207.03 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $99.33 | 2024-2025 | Recorlev |
| Pfizer INC. | $78.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $72.28 | 2023-2025 | Farxiga, Fasenra |
| Inspire Medical Systems, INC. | $71.09 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $62.04 | 2023 | Quviviq |
| Lilly USA, LLC | $45.99 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $43.12 | 2023-2024 | Rexulti |
| Alnylam Pharmaceuticals INC. | $42.68 | 2025 | Amvuttra |
| Baxter Healthcare | $34.15 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.95 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $30.02 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.92 | 2024 | Minimed 780g |
| Regeneron Healthcare Solutions, INC. | $25.34 | 2025 | Evkeeza |
| Bracco Diagnostics INC. | $20.98 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.67 | 2025 | Pyrukynd |
| Dexcom, INC. | $19.01 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2024 | |
| Recordati_rare_diseases_inc. | $15.78 | 2025 | Isturisa |
| Echosens North America, INC. | $14.12 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Govindan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.